Upgrade Alert for NuVasive (NUVA)
NuVasive (NASDAQ:NUVA) was upgraded from Neutral to Overweight at JP Morgan today. The stock closed yesterday at $61.42 on volume of 769,000 shares, above average daily volume of 754,000.
NuVasive, Inc. designs, develops, and markets products for the surgical treatment of spine disorders. The Company's products include Maximum Access Surgery (MAS) and Fusion products.
NuVasive (NASDAQ:NUVA) defies analysts with a current price ($61.42) 4.8% above its average consensus price target of $58.47. NuVasive shares have support at the 200-day moving average (MA) of $49.69 and additional support at the 50-day MA of $48.04.
NuVasive share prices have moved between a 52-week high of $62.33 and a 52-week low of $36.81 and closed yesterday at 67% above that low price at $61.42 per share. The 200-day and 50-day moving averages have moved 0.12% higher and 2.23% higher over the past week, respectively.
SmarTrend recommended that subscribers consider buying shares of NuVasive on March 4th, 2016 as our proprietary SmarTrend analytics indicated a new Uptrend was in progress when shares hit $43.48. Since that recommendation, shares of NuVasive have risen 40.3%. We continue to monitor NUVA for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.
Keywords: analyst upgrades/downgrades nuvasive